Integrative Health Technologies, Inc. (IHTI)
San Antonio, TX, US
Integrative Health Technologies, Inc. offers a variety of professional services to the healthcare and nutritional sectors, including paid clinical trials, research and development initiatives, and specialized consulting and analytical testing. The company boasts an extensive historical database, comprising over 30,000 diagnostic tests collected over two decades, which is utilized for tracking disease patterns. Additionally, it deploys both mobile and fixed dual-energy X-ray absorptiometry (DEXA) units designed to accurately assess total and regional bone density, as well as body fat and lean mass. The firm also furnishes comprehensive blood chemistry reports, detailing 43 distinct biochemical markers such as HDL, LDL, C-reactive protein, thyroid function, electrolyte balance, red and white blood cell counts, and glucose levels. Established in 1999, Integrative Health Technologies, Inc. is headquartered in San Antonio, Texas.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -95.00% | -95.00% | -95.00% | -95.00% | -95.00% | -95.00% | -99.33% | -98.67% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+2,909.0% ★ Q3'07: +30.0% (vs Q3'06)
-
EPS growth Medical - Diagnostics & Research: +30.8%+100.0% ★ Q3'07: -76.1% (vs Q3'06)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+8.7% Q3'07: -133.7% (vs Q3'06)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+8.7% Q3'07: +47.4% (vs Q3'06)
-
ROIC Medical - Diagnostics & Research: +5.2%+0.5% Q3'07: +1.7% (vs Q3'06)
-
Share dilution Medical - Diagnostics & Research: 0.0%-100.0% ★ Q3'07: +4,394.1% (vs Q3'06)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.00× ★ Q3'07: 0.00× (vs Q3'06)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gilbert R. Kaats | Chairman, Chief Executive Officer, President, Chief Financial Officer & Member of Scientific Advisory Board | — | male |
| Shirlie Kaats | Secretary & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IHTI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
